Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 41

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 41
---
C with BAT and at EOS, respectively, while 100% of
the subjects who received AP-SA02 clinically responded (p = 0.025: TOC BAT; p = 0.020: EOS).

<div align='center'>4</div>

Additionally,
faster time to a negative blood culture and decline of key predictors of mortality and complications in SAB, including interleukin-10
and C-reactive protein, support the improved responder rates in subjects treated with AP-SA02.

We previously demonstrated
the persistence of AP-SA02 in the IV space on multiple days one hour post IV push. These trial results support AP-SA02 homing to different
sites of infection, presumably penetrating biofilms, and infecting and lysing the target S. aureus bacteria, independent of antibiotic
resistance patterns and site of infection.

The results from our Phase
1b/2a diSArm study are an important step forward in our effort to confirm the potent antimicrobial activity of phage therapy and the
completion of the study represents a significant milestone in the development of AP-SA02, moving us one step closer to introducing an
effective new treatment option to patients suffering from complicated S. aureus bacteremia. This is the first clear evidence in
a randomized controlled trial of the efficacy of phage against a serious systemic pathogen that is responsible for significant morbidity
and mortality in the United States.

Findings from the Phase 1b/2a
study, including the favorable safety and tolerability profile of AP-SA02, inform the design of a larger definitive efficacy study to
demonstrate superiority of AP-SA02 in treating complicated S. aureus bacteremia, and form the basis for an end-of-Phase 2 meeting
with the FDA which the Company plans to hold in the second half of 2025. We are committed to developing a superiority pivotal trial focused
on phage as an alternative to broad-spectrum antibiotics and/or antibiotic sparing to decrease the utilization of broad-spectrum antibiotics
and their detrimental impact on the normal human microbiome.

Additional Clinical Indications for AP-SA02

On
August 1, 2022, we announced FDA approval to proceed with our IND application for AP-SA02 in a second indication, prosthetic joint
infections (“PJI”) with S. aureus. We had planned to initiate a Phase 1b/2a trial; however, in light of the growing
concerns of both PJI and wound